These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31088239)

  • 1. Clinical significance of signs of autoimmune colitis in
    Lang N; Dick J; Slynko A; Schulz C; Dimitrakopoulou-Strauss A; Sachpekidis C; Enk AH; Hassel JC
    Immunotherapy; 2019 Jun; 11(8):667-676. PubMed ID: 31088239
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
    Wachsmann JW; Ganti R; Peng F
    Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
    J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
    Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
    Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute number of new lesions on
    Anwar H; Sachpekidis C; Winkler J; Kopp-Schneider A; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.
    Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V
    Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal studies of the
    Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].
    Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C
    Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
    Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of baseline metabolic tumor volume measured on
    Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
    Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.
    Barina AR; Bashir MR; Howard BA; Hanks BA; Salama AK; Jaffe TA
    Abdom Radiol (NY); 2016 Feb; 41(2):207-14. PubMed ID: 26867901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of interim
    Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab-induced colitis on FDG PET/CT.
    Lyall A; Vargas HA; Carvajal RD; Ulaner G
    Clin Nucl Med; 2012 Jun; 37(6):629-30. PubMed ID: 22614208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can benign lymphoid tissue changes in
    Sachpekidis C; Larribère L; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
    Cancer Immunol Immunother; 2019 Feb; 68(2):297-303. PubMed ID: 30478475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
    van der Hiel B; Blank CU; Haanen JB; Stokkel MP
    Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab.
    Dittrich D; Pyka T; Scheidhauer K; Lütje S; Essler M; Bundschuh RA
    Nuklearmedizin; 2020 Jun; 59(3):228-234. PubMed ID: 32259852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.
    Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
    Hell J Nucl Med; 2017; 20(3):251-253. PubMed ID: 29177265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.